Partner A was OptimizeRx’s largest revenue line in fiscal 2024, bringing in $26.82M of $92.11M (29%).
| Concentration Risk Type | FY 2014 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2024 |
|---|---|---|---|---|---|---|
| Partner A | $33.04M | $26.82M | ||||
| Partner B | $9.55M | $25.98M | ||||
| Customer A | $14.27M | $15.56M | ||||
| Customer B | $14.27M | $12.76M | ||||
| Partner C | $9.55M | $11.00M | ||||
| Partner B[Member] | — | — | ||||
| Customer D Lilly | — | — | ||||
| Revenues | — | — | ||||
| Customer E Pfizer | — | — | ||||
| Customer E | — | — | ||||
| Customer C | — | — | ||||
| Partner D | — | — | ||||
| Customer D | — | — | ||||
| Total | $80.69M | $92.11M |
OptimizeRx brought in $92.11M from its five revenue lines in fiscal 2024, the year ended December 31, 2024. That was up 14.2% from $80.69M in fiscal 2021, the previous year with figures. Partner A was the largest at $26.82M (29.1%), ahead of Partner B at $25.98M (28.2%) and Customer A at $15.56M (16.9%). The other two revenue lines brought in $23.76M combined.
Compared with fiscal 2021, the previous year with figures, Partner B grew fastest, up 171.9% to $25.98M, while Partner A fell the most, down 18.8% to $26.82M. From fiscal 2021 to 2024, combined revenue from these revenue lines grew from $80.69M to $92.11M, a compound annual growth rate of 4.5%. Partner A's share of the total fell from 40.9% to 29.1%.
Revenue Recognized Over Time was OptimizeRx’s largest revenue line in fiscal 2024, bringing in $85.47M of $92.13M (93%).
| Timing of Transfer of Good or Service | FY 2023 | FY 2024 |
|---|---|---|
| Revenue Recognized Over Time | $63.53M | $85.47M |
| Revenue Recognized At A Point In Time | $8.00M | $6.66M |
| Total | $71.52M | $92.13M |
OptimizeRx brought in $92.13M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. That was up 28.8% from $71.52M in fiscal 2023. Revenue Recognized Over Time was the largest at $85.47M (92.8%), ahead of Revenue Recognized At A Point In Time at $6.66M (7.2%).
Compared with fiscal 2023, Revenue Recognized Over Time grew 34.5% to $85.47M, while Revenue Recognized At A Point In Time fell 16.7% to $6.66M.
OptimizeRx (OPRX) reports its revenue by concentration risk type and by timing of transfer of good or service. In fiscal 2024, Partner A was its largest revenue line, bringing in $26.82M (29.1% of the total), followed by Partner B at $25.98M (28.2%).
Partner A was OptimizeRx's largest revenue line in fiscal 2024, bringing in $26.82M, or 29.1% of the $92.11M total across its five revenue lines.
Revenue Recognized Over Time grew faster than Revenue Recognized At A Point In Time in fiscal 2024, up 34.5% from $63.53M to $85.47M. Revenue Recognized At A Point In Time fell 16.7% to $6.66M.
Every figure comes from OptimizeRx's annual financial filings, as reported. Each line keeps the name OptimizeRx gives it, and years follow its fiscal calendar.
OptimizeRx's revenue by concentration risk type goes back to fiscal 2014, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.